Tags

Type your tag names separated by a space and hit enter

Neuraminidase antibody response to inactivated influenza virus vaccine following intranasal and intramuscular vaccination.
Isr Med Assoc J. 2006 Mar; 8(3):155-8.IM

Abstract

BACKGROUND

The evaluation of influenza vaccine activity and potency are based on the immune response to hemagglutinin, and protection is indicated when the titer of hemagglutination inhibition serum antibody is > or = 1:40. Neuraminidase, the second surface glycoprotein, may also have a role in protection, but little information is available on the immunologic response to this component.

OBJECTIVES

To determine whether any response to neuraminidase is evoked by intranasal immunization with a novel, whole, inactivated anti-influenza vaccine.

METHODS

This study was part of a more comprehensive study of mucosal and serum immune response to this vaccine. Fifty-four young adults were immunized intranasally, 9 intramuscularly and 18 received a placebo. Twenty-three elderly people were immunized intramuscularly, and 21 elderly and 17 children were immunized intranasally. Serum and nasal antibodies to antigens N1 and N2 were determined by the lectin neuraminidase test.

RESULTS

Serum response following intranasal vaccination was lower than after intramuscular vaccination, and ranged from 21.4 to 35.3% and 33.3 to 64.7% following intranasal vaccination and from 52.2 to 77.8% and 47.8 to 88.9% after intramuscular vaccination, to N1 and N2 respectively. Nasal antibody response was low and was found only after intranasal vaccination, and response to N2 was better than to the N1 antigen.

CONCLUSIONS

It may be beneficial if future vaccines would include competent hemagglutinin and neuraminidase, which would afford a higher level of protection.

Authors+Show Affiliations

Muhamed G
Department of Virology, Hebrew University-Hadassah Medical School, Jerusalem, Israel.
Greenbaum E
No affiliation info available
Zakay-Rones Z
No affiliation info available

MeSH

Administration, IntranasalAdultAgedAntibodiesChildEnzyme-Linked Immunosorbent AssayHumansInfluenza A virusInfluenza VaccinesInfluenza, HumanInjections, IntramuscularNasal MucosaNeuraminidaseVaccinationVaccines, Inactivated

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

16599048

Citation

Muhamed, Gaber, et al. "Neuraminidase Antibody Response to Inactivated Influenza Virus Vaccine Following Intranasal and Intramuscular Vaccination." The Israel Medical Association Journal : IMAJ, vol. 8, no. 3, 2006, pp. 155-8.
Muhamed G, Greenbaum E, Zakay-Rones Z. Neuraminidase antibody response to inactivated influenza virus vaccine following intranasal and intramuscular vaccination. Isr Med Assoc J. 2006;8(3):155-8.
Muhamed, G., Greenbaum, E., & Zakay-Rones, Z. (2006). Neuraminidase antibody response to inactivated influenza virus vaccine following intranasal and intramuscular vaccination. The Israel Medical Association Journal : IMAJ, 8(3), 155-8.
Muhamed G, Greenbaum E, Zakay-Rones Z. Neuraminidase Antibody Response to Inactivated Influenza Virus Vaccine Following Intranasal and Intramuscular Vaccination. Isr Med Assoc J. 2006;8(3):155-8. PubMed PMID: 16599048.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Neuraminidase antibody response to inactivated influenza virus vaccine following intranasal and intramuscular vaccination. AU - Muhamed,Gaber, AU - Greenbaum,Evgenia, AU - Zakay-Rones,Zichria, PY - 2006/4/8/pubmed PY - 2006/4/19/medline PY - 2006/4/8/entrez SP - 155 EP - 8 JF - The Israel Medical Association journal : IMAJ JO - Isr Med Assoc J VL - 8 IS - 3 N2 - BACKGROUND: The evaluation of influenza vaccine activity and potency are based on the immune response to hemagglutinin, and protection is indicated when the titer of hemagglutination inhibition serum antibody is > or = 1:40. Neuraminidase, the second surface glycoprotein, may also have a role in protection, but little information is available on the immunologic response to this component. OBJECTIVES: To determine whether any response to neuraminidase is evoked by intranasal immunization with a novel, whole, inactivated anti-influenza vaccine. METHODS: This study was part of a more comprehensive study of mucosal and serum immune response to this vaccine. Fifty-four young adults were immunized intranasally, 9 intramuscularly and 18 received a placebo. Twenty-three elderly people were immunized intramuscularly, and 21 elderly and 17 children were immunized intranasally. Serum and nasal antibodies to antigens N1 and N2 were determined by the lectin neuraminidase test. RESULTS: Serum response following intranasal vaccination was lower than after intramuscular vaccination, and ranged from 21.4 to 35.3% and 33.3 to 64.7% following intranasal vaccination and from 52.2 to 77.8% and 47.8 to 88.9% after intramuscular vaccination, to N1 and N2 respectively. Nasal antibody response was low and was found only after intranasal vaccination, and response to N2 was better than to the N1 antigen. CONCLUSIONS: It may be beneficial if future vaccines would include competent hemagglutinin and neuraminidase, which would afford a higher level of protection. SN - 1565-1088 UR - https://www.unboundmedicine.com/medline/citation/16599048/Neuraminidase_antibody_response_to_inactivated_influenza_virus_vaccine_following_intranasal_and_intramuscular_vaccination_ DB - PRIME DP - Unbound Medicine ER -